Valuation: Vericel Corporation

Market Cap 2.93B 2.65B 2.45B 2.21B 4.18B 275B 4.3B 29.36B 11.67B 147B 11B 10.76B 469B P/E 2026 *
75.7x
P/E 2027 * 60.8x
Enterprise Value 2.93B 2.65B 2.45B 2.21B 4.18B 275B 4.3B 29.36B 11.67B 147B 11B 10.76B 469B EV / Sales 2026 *
8.49x
EV / Sales 2027 * 7.36x
Free-Float
98.81%
Yield 2026 *
-
Yield 2027 * -
1 day+0.53%
1 week+4.71%
Current month+42.05%
1 month+41.91%
3 months+28.40%
6 months+74.15%
Current year+58.82%
1 week 55.6
Extreme 55.6
59.75
1 month 39.44
Extreme 39.44
59.75
Current year 28.95
Extreme 28.95
59.75
1 year 28.95
Extreme 28.95
59.75
3 years 28.95
Extreme 28.95
63
5 years 17.3
Extreme 17.3
63
10 years 2.15
Extreme 2.15
68.94
Manager TitleAgeSince
Chief Executive Officer 62 01/03/2013
Director of Finance/CFO 51 25/01/2021
Chief Tech/Sci/R&D Officer - 01/01/2024
Director TitleAgeSince
Director/Board Member 71 28/09/2005
Chairman 75 05/10/2012
Director/Board Member 57 23/08/2013
Date Insider Type Main position Quantity % Market Cap. Importance
5/11/26 Exercice

Chairman

9,000 0.0176%
5/11/26 Exercice

General Counsel

45,000 0.0879%
5/11/26 Exercice

Controller/Auditor

4,500 0.0088%
Change 5-day change 1-year change 3-year change Capi.($)
+0.51%+4.71%+43.55%+68.45% 2.93B
+0.87%+5.18%+39.23%+132.44% 1,271B
+1.57%+3.30%+46.14%+93.27% 683B
+0.68%+1.19%+26.91%+112.63% 520B
-0.36%+3.51%+39.36%+69.21% 389B
-0.15%-0.53%+57.05%+42.43% 362B
+0.29%+0.68%+26.71%+58.33% 304B
+0.90%+0.26%+3.50%+36.28% 286B
-0.12%+0.81%+38.14%+74.04% 253B
+0.61%+0.65%+34.16%+124.17% 208B
Average +0.48%+2.65%+35.47%+81.13% 428B
Weighted average by Cap. +0.64%+2.68%+36.77%+94.83%

Financials

2026 *2027 *
Net sales 345M 312M 288M 261M 492M 32.46B 507M 3.46B 1.37B 17.35B 1.3B 1.27B 55.23B 398M 360M 333M 301M 568M 37.45B 585M 3.99B 1.59B 20.02B 1.49B 1.46B 63.72B
Net income 40.61M 36.72M 33.9M 30.68M 57.9M 3.82B 59.64M 407M 162M 2.04B 152M 149M 6.5B 51.08M 46.19M 42.64M 38.59M 72.83M 4.8B 75.01M 512M 203M 2.57B 192M 188M 8.17B
Net Debt - -
Projected Income Statement - Annual - Vericel Corporation
Logo Vericel Corporation
Vericel Corporation is a provider of advanced therapies for sports medicine and severe burn care markets. It has a differentiated portfolio of cell therapy and specialty biologic products. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Employees
398
Date Price Change Volume
14/11/26 USD 57.30 -0.21% 45,710
12/11/26 USD 57.42 -3.41% 826,630
11/11/26 USD 59.45 +0.71% 809,563
10/11/26 USD 59.03 +1.10% 1,331,160
09/11/26 USD 58.39 +6.90% 1,750,784
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Vericel Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
57.42USD
Average target price
65.43USD
Spread / Average Target
+13.95%
  1. Stock Market
  2. Stocks
  3. VCEL Stock